CN103239635A - Anti-cancer pain oral liquid - Google Patents
Anti-cancer pain oral liquid Download PDFInfo
- Publication number
- CN103239635A CN103239635A CN2012100303113A CN201210030311A CN103239635A CN 103239635 A CN103239635 A CN 103239635A CN 2012100303113 A CN2012100303113 A CN 2012100303113A CN 201210030311 A CN201210030311 A CN 201210030311A CN 103239635 A CN103239635 A CN 103239635A
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- filtrate
- time
- pain
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an anti-cancer pain oral liquid, which is prepared by processing cordyceps sinensis, monkshood, aconite root, asparagus, celandine, and pseudo-ginseng by a traditional water boiling method. The oral liquid of the present invention has the characteristics of wide drug sources, simple production process, and good effect, and can be widely used for anti-cancer pain of various early, middle and late cancer patients.
Description
Technical field
The present invention relates to a kind of medicine of anticancer pain.
Background technology
The existing medicine that is used for the treatment of cancer pain is a lot, mostly be Western medicine, though Western medicine has curative effect preferably in the process for the treatment of cancer pain, but side effect is big, should not take for a long time, and Chinese medicine also is useful on treats cancer pain, but poor effect.
Summary of the invention
Purpose of the present invention is exactly to provide a kind of Chinese medicine preparation that is used for the treatment of cancer pain at above-mentioned situation.Purpose of the present invention can realize by following scheme: a kind of anticancer pain oral liquid is to be that the preparation of raw material of weight portion forms: Cordyceps 4.85-5.8 by following consumption, Radix Aconiti Lateralis Preparata 35.4-41, Radix Aconiti 16.4-17.7, Germinatus Phragmitis 16.4-17.7, Herba Chelidonii 16.4-17.7, Radix Notoginseng 4.85-5.8.Processing technology of the present invention is as follows: the above-mentioned raw material for preparing is mixed, and add in the water of 3 times of its weight and soaked 30-60 minutes, under 100 ℃ temperature, decocted 60-80 minutes then, win time filtrate of filtration, the water that filtering residue is put into 3 times of its weight again decocts, under 100 ℃ temperature, decocted 50-60 minute, refilter, get filtrate for the second time, for the first time filtrate and for the second time filtrate mix and concentrate, the degree that concentrates is that the weight of gained concentrated solution is filtrate for the first time and 10% getting final product of filtrate gross weight for the second time, and resultant concentrated solution is anticancer pain oral liquid of the present invention.The present invention has characteristics such as the medicine source is wide, and processing technology is simple, and is effective, and the anticancer pain that can be widely used in various early, middle and late cancer patients is used.
Anticancer pain oral liquid of the present invention has carried out experimentation through Beijing University of Chinese Medicine, and the present invention is to the research of mice experiment of analgesic:
1. experiment material
1.1 animal: the ICR mice, the male and female dual-purpose, body weight 18-22g purchases in Haidian, Beijing prosperity laboratory animal plant licence numbering SCXK-(army) 2007-004.
1.2 medicine and reagent:
1.2.1 be subjected to the anticancer pain oral liquid of reagent the present invention.
1.2.2 positive control drug can general fragrant sheet, Industrial Co., Ltd of traditional Chinese medicines group, authentication code: the accurate word H20000514 of traditional Chinese medicines, lot number 100814.
1.2.3 glacial acetic acid (HAc), analytical pure, the Beijing Chemical Plant produces.
1.3 instrument: intelligent hot-plate instrument, model YLS-6B type, Shandong Academy of Medical Sciences's equipment station product.
2. method and result
2.1 the anticancer pain oral liquid of the present invention is to the pain caused influence (writhing method) of mouse peritoneal injection acetic acid
2.1.1 reagent is prepared 0.6% glacial acetic acid and is prepared with the dark liquid of normal saline: accurately draw 100% glacial acetic acid 0.3ml, be dissolved among the normal saline solution 50ml of pH7-7.2.
2.1.1 grouping and experiment: 90 of mices, be divided into matched group, can organize (66.5mg/kg is equivalent to 10 times of human body consumption) by general sweet smell, the anticancer pain oral liquid of the present invention is big, in, low dose (is respectively 9.1g/kg, 4.6g/kg, 2.3g/kg) totally 5 groups, give the equal-volume solvent respectively, can general sweet smell and the cancer pain oral liquid of various dose, every group about 19, each organizes 1h after the administration, lumbar injection 06.%HAc normal saline solution 0.2ml/ only immediately, observe mouse writhing reaction times (abdominal part indent in 30 minutes, stretch hind leg, buttocks is raised) and writhing response rate and record the result, be calculated as follows each group percentage rate that eases pain.Statistical procedures adopts SPSS software to organize a t check.The results are shown in Table 1.The result shows: positive control drug can general sweet smell and is subjected to large, medium and small three dosage of the anticancer pain oral liquid of reagent the present invention all can significantly reduce the number of times (p＜0.01) of the mouse writhing reaction that acetic acid causes, and along with the dosage of analgesic effect with medicine increases.
Analgesic response percentage rate=(matched group writhing response number-administration group writhing response number
÷Matched group writhing response number) * 100%
Table 1: the influence that the mice that the anticancer pain oral liquid of the present invention causes HAc is suffered from abdominal pain
Annotate: compare * * p＜0.01 with matched group
2.2 the anticancer pain oral liquid of the present invention is to the warm analgesic activity (hot plate method) that causes mice pain
2.2.1 open intelligent hot-plate instrument, make hot plate temperature control at 55 ± 0.5 ℃, hot plate preheating 10 minutes.
2.2.2 grouping and experiment: 100 of mices, at first pass through preliminary election, mice is placed on the hot plate, mice is from being placed on the hot plate to occurring licking metapedes required time (second) as the pain threshold of this Mus.Allly lick the metapedes time less than 5 seconds or give it up greater than 30 seconds or leaper.Qualified mice is divided into large, medium and small group of matched group, can be general fragrant group, anticancer pain oral liquid at random, and every treated animal number sees Table 2, and its normal pain threshold of replication is got two subnormal threshold of pain meansigma methodss, as pain threshold before this Mus administration.
2.2.3 observe the analgesic activity of anticancer pain oral liquid: with matched group, can be general (4.6g/kg), little (2.3g/kg) dosage group in the fragrant group (66.5mg/kg is equivalent to 10 times of human body consumption), anticancer pain oral liquid big (9.1g/kg), each group give respectively the equal-volume solvent, can general sweet smell and the anticancer pain oral liquid of various dose, measured the pain threshold of mice after the experiment administration on the same day in 30,60,90 minutes respectively.Statistical procedures adopts SPSS software to carry out t check between variance analysis and group.The results are shown in Table 2.The result show can general sweet smell and the big or middle dosage of anticancer pain oral liquid all can the significant prolongation mice threshold of pain (p＜0.01, p＜0.05) in the 30min to 90min after administration._
Table 2: anticancer pain oral liquid is to the influence (hot plate method) of mice analgesic activity (X ± S)
Annotate: compare * p＜0.05, * * p＜0.01 with matched group
3. brief summary and conclusion
3.1 positive drug can general sweet smell can significantly reduce the number of times (p＜0.01) of the mouse writhing reaction that glacial acetic acid causes, and the analgesia rate reaches 81.5%.All can cause the threshold of pain (p＜0.01) bitterly by significant prolongation mice Yin Wenre in the 30min to 90min after the administration.
3.2 (9.1g/kg, 4.6g/kg 2.3g/kg) all can significantly reduce the number of times (p＜0.01) of the mouse writhing reaction that glacial acetic acid causes after the administration, and analgesia rate of each group are respectively 71.5%, 46.4% and 37.4% to the large, medium and small dosage of anticancer pain oral liquid.Between each dosage group tangible dose-effect relationship is arranged.The result shows that anticancer pain oral liquid has significant analgesic activity to the mouse peritoneal pain due to the chemical factor.
3.3 the big or middle dosage of anticancer pain oral liquid (9.1g/kg, 4.6g/kg) pain valve (p＜0.01, p＜0.05) that all can the significant prolongation mice in the 30min to 90min after the administration.Show that anticancer pain oral liquid has significant analgesic activity to the warm mice pain that causes.
Conclusion: the anticancer pain oral liquid of the present invention has significant analgesic activity.
Claims (1)
1. anticancer pain oral liquid, it is characterized in that by following consumption being that the preparation of raw material of weight portion forms: Cordyceps 4.85-5.8, Radix Aconiti Lateralis Preparata 35.4-41, Radix Aconiti 16.4-17.7, Germinatus Phragmitis 16.4-17.7, Herba Chelidonii 16.4-17.7, Radix Notoginseng 4.85-5.8, processing technology of the present invention is as follows: the above-mentioned raw material for preparing is mixed, and add in the water of 3 times of its weight and soaked 30-60 minutes, under 100 ℃ temperature, decocted 60-80 minutes then, filter time filtrate of winning, the water that filtering residue is put into 3 times of its weight again decocts, under 100 ℃ temperature, decocted 50-60 minute, refilter, get filtrate for the second time, for the first time filtrate and for the second time filtrate mix and concentrate, the degree that concentrates is that the weight of gained concentrated solution is filtrate for the first time and 10% getting final product of filtrate gross weight for the second time.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100303113A CN103239635A (en) | 2012-02-13 | 2012-02-13 | Anti-cancer pain oral liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100303113A CN103239635A (en) | 2012-02-13 | 2012-02-13 | Anti-cancer pain oral liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103239635A true CN103239635A (en) | 2013-08-14 |
Family
ID=48919738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100303113A Pending CN103239635A (en) | 2012-02-13 | 2012-02-13 | Anti-cancer pain oral liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103239635A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115054664A (en) * | 2022-07-25 | 2022-09-16 | 北京康恩泰生物医药有限公司 | A pharmaceutical composition for treating cancer pain, and its preparation method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1240659A (en) * | 1998-07-03 | 2000-01-12 | 周田明 | Anticancer and antalgesic oral liquid |
| CN102293296A (en) * | 2011-07-13 | 2011-12-28 | 王本荣 | Blood-pressure-reducing anticancer tea |
-
2012
- 2012-02-13 CN CN2012100303113A patent/CN103239635A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1240659A (en) * | 1998-07-03 | 2000-01-12 | 周田明 | Anticancer and antalgesic oral liquid |
| CN102293296A (en) * | 2011-07-13 | 2011-12-28 | 王本荣 | Blood-pressure-reducing anticancer tea |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115054664A (en) * | 2022-07-25 | 2022-09-16 | 北京康恩泰生物医药有限公司 | A pharmaceutical composition for treating cancer pain, and its preparation method |
| WO2024021826A1 (en) * | 2022-07-25 | 2024-02-01 | 周田明 | Pharmaceutical composition for treating cancerous pain and preparation method therefor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102988827B (en) | Dendrobium officinale granula | |
| CN102370695B (en) | Qinglongyi active extract, its preparation method and its application | |
| CN104474008A (en) | Honeysuckle prickly heat water and preparation method thereof | |
| CN103690747B (en) | A kind of Traditional Chinese medicine composition for foot bath | |
| CN103239635A (en) | Anti-cancer pain oral liquid | |
| CN105853726A (en) | Method for preparing skin soothing liquid | |
| CN106236795A (en) | A kind of Chinese medicine preparation with bacteriostasis and production method | |
| CN102038799B (en) | Application of breast lump-elimination preparation in preparing medicines for treating dysmenorrhea | |
| CN104740581B (en) | A kind of application of cold asthma patch of fragrant fiber crops and its detection method | |
| CN102362877A (en) | Pouzolzia extract, preparation method thereof, and application thereof | |
| CN105998654A (en) | Medicinal preparation for treating cerebral palsy | |
| CN106074643B (en) | Application of acanthopanax giraldii harms leaf and extract thereof in preparing anti-fatigue medicine or health food | |
| CN103800636A (en) | Oral liquid for treating children hyperactivity | |
| CN103272186B (en) | Traditional Chinese medicine for curing curettage amenorrhea | |
| CN102389552B (en) | External medicinal liquor used for treating rheumatic ostalgia | |
| CN103479707B (en) | Preparation method of total platycodin capable of dispelling effects of alcohol | |
| CN108210802A (en) | It is a kind of treat osteoproliferation, joint pain composition and preparation method thereof | |
| CN102872216A (en) | Traditional Chinese medicine preparation containing aconitum sungpanense alkaloid | |
| CN101181336A (en) | Method for refining valid target of bitter gourd for dropping blood sugar | |
| CN105288289A (en) | Traditional Chinese medicine composition for treating lung stroke | |
| CN101658561B (en) | Painkiller traditional Chinese medicine, capsule and preparation process thereof | |
| CN104189048A (en) | Traditional Chinese medicine composition for pain relief, and preparation method and application thereof | |
| CN103536845B (en) | Resolving depression hepatic growth factor is preparing the application in anti-inflammation analgesia medicine | |
| CN103565864A (en) | Pain relieving effect of apocynum venetum extract on human body and preparation method of apocynum venetum extract | |
| CN104546961B (en) | Radix Urenae Lobatae extract is preparing the purposes for the treatment of and/or prevention cancer drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130814 |